FDA plans to replace animal testing with AI – “Paradigm shift”

The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership ...

Astra Zeneca's Covid-19 vaccine Vaxzevria is being withdrawn worldwide

AstraZeneca initiates a worldwide withdrawal of its Covid vaccine Vaxzevria. The measure is taken just months after the company admitted the vaccine can cause a...

Pharma Relations AB

Sarah Lidé: ”Artificial intelligence must not replace authentic interactions”

Artificial intelligence must never become a replacement for authentic, even if messy, interactions with our fellow humankind, Sarah Lifé, Deputy CEO at Medicon ...

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

GSK acquires oncology research company

GSK acquires the American biotechnology company Idrx for up to 1.15 billion dollars.

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Tidig tilläggsbehandling kan rädda liv på hjärtpatienter enligt studie

Tidig behandling med blodfettsänkande läkemedel ger en bättre prognos för patienter med hjärtinfarkt jämfört med en sent insatt behandling eller ingen behandlin...

“A major energy boost for the entire cancer vaccine field”

The development of cancer vaccines has accelerated in recent years. Norwegian Ultimovacs is one of the companies attempting to develop a new type of treatment l...

Japanese pharma to buy US drugmaker for $2.4 bln

Japanese Ono Pharmaceutical buys the American cancer drug developer Deciphera Pharmaceuticals in one of the largest acquisitions in the industry so far this year.

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

Pfizer värvar FDA-topp – kritiseras hårt

Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.

An increasing number of people are falling ill with TBE – “Much more research is needed”

Tick-borne meningitis, or TBE, is an increasingly common disease in Sweden. Currently, there is a vaccine against the disease but no drugs. Researcher Anna Över...

EQT säljer Karo Healthcare för 27 miljarder

Riskkapitalbolaget KKR förvärvar det svenska konsumenthälsobolaget Karo Healthcare från EQT.

Amrop Malmö AB

USA upprättar databas över autismpatienter – ska forska kring orsakerna

USA:s hälsomyndigheter ska skapa en databas över autismpatienter för att kunna studera orsakerna till diagnosen. Det meddelade landets hälsominister Robert F. K...

Europeiska läkemedelsaktier rasar efter Trumps tullhot

Europeiska läkemedelsbolag faller kraftigt efter att USA:s president Donald Trump flaggat för att stora tullhöjningar är på gång mot branschen.

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Samuel Lagercrantz: A special kind of hellishness afflicts post-COVID patients

In addition to the disease itself those suffering from post-COVID have to deal with people who try to label them as hypochondriacs, writes Samuel Lagercrantz in an editorial.

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Korbinian Löbmann leads scientific meeting on drug formulation: High activity in the field

Korbinian Löbmann has moderated New Updates in Drug Formulation & Bioavailability several times before. Now he is once again taking on the scientific meeting. L...